uniQure Inc.: uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients
~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ~
LEXINGTON, Mass. and AMSTERDAM, May 13, 2021showing clinical benefit in hemophilia B patients with pre-existing neutralizing antibodies (NAbs) to AAV5, and no relationship between AAV5 NAbs and the tolerability of the therapy.
The data were featured on Wednesday, May 12, 2021 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in an oral presentation by Michael Recht, M.D., Ph.D., M.B.A., professor of pediatrics, division of hematology and oncology at the Oregon Health & Science University School of Medicine. These data were previously presented at a medical meeting late last year.
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients
~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ~
LEXINGTON, Mass. and AMSTERDAM, May 13, 2021 (GLOBE NEWSWIRE) uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, yesterday presented 26-week clinical data from the pivotal, Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec showing clinical benefit in hemophilia B patients with pre-existing neutralizing antibodies (NAbs) to AAV5, and no relationship between AAV5 NAbs and the tolerability of the therapy.
The data were featured on Wednesday, May 12, 2021 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in an oral presentation by Michael Recht, M.D., Ph.D., M.B.A., professor of pediatrics, division of hematology and oncology at the Oregon Health & Science University School
Doctor Radio on SiriusXM is Now Free Throughout Duration of Pandemic
SiriusXM announces its Doctor Radio channel 110 will be free to the general public to help guide and inform as the Covid-19 virus causes record hospitalizations and deaths throughout the country. The free access and new programming on Doctor Radio coincides with the Food and Drug Administration’s (FDA) expected approval of a Covid-19 vaccine under Emergency Use Authorization.
Since the beginning of the pandemic, SiriusXM in conjunction with NYU Langone Health, has dedicated the Doctor Radio channel to providing the public with the latest information on the coronavirus outbreak, while continuing to address everyday health concerns. Listeners can access the channel online via the browsers on their computers or phones, as well as their vehicles installed with the majority of SiriusXM radios, even if they’re not a paid subscriber to the service, a media release from Sirius XM Holdings Inc explains.
SiriusXM and NYU Langone Health Provide Free Access to Doctor Radio Channel, Offering Covid-19 Updates and Expert Advice marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.